Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Sicurezza ed efficacia a lungo termine di Odevixibat nei pazienti con sindrome di Alagille (ASSERT-EXT)

20 ottobre 2026 aggiornato da: Albireo, an Ipsen Company

Uno studio in aperto per valutare la sicurezza e l'efficacia a lungo termine di Odevixibat (A4250) in pazienti con sindrome di Alagille (ASSERT-EXT)

The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS).

The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis).

The drug used for the study is odevixibat and was authorized for the treatment of cholestatic pruritus in infants with ALGS over 12 months of age by the United States Food and Drug Administration on 13 June 2023.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This Phase 3, open-label, multi-center extension study will have two groups of participants: Cohort 1 (participants who participated in Study A4250-012 [NCT04674761; ASSERT] and meet the entry criteria for this study) and Cohort 2 (infants under 12 months of age) with ALGS.

The study will consist of 2 or 3 periods:

  1. A 'Treatment period' of 72 weeks (cohort 1) or 12 weeks (cohort 2). Participants will visit the clinic every 4 to 12 weeks and will receive a dose of 120 μg/kg odevixibat daily.
  2. An 'Optional extension period' where participants who wish to continue receiving odevixibat after the 'treatment period' will have the opportunity to remain on treatment with visits every 16 weeks until the drug is commercially available. The optional extension is available provided continued use is supported by the risk-benefit profile, the participant has not been previously withdrawn or discontinued from the study, and the study is not terminated by the Sponsor.
  3. A 'Safety follow-up period' of 4 weeks (cohort 1) or 2 weeks (cohort 2). The Safety Follow-up Period will not occur for those who remain on treatment in the optional extension period.

Participants will need to complete an e-diary and questionnaires throughout the study (cohort 1 only). Participants will undergo blood samplings, urine collections (cohort 1 only), physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

62

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Brussels, Belgio, 1200
        • Cliniques Universitaires Saint-Luc Bruxelles
      • Bron, Francia, 69677
        • Hôpital Femme Mère Enfant de Lyon
      • Lille, Francia
        • Antenne pediatrique du CIC-Hopital Jeanne De Flandre
      • Paris, Francia, 75015
        • Hopital Necker Enfants Malades
      • Berlin, Germania, 13353
        • Charité - Universitätsmedizin Berlin
      • Hanover, Germania, 30625
        • Medizinische Hochschul
      • Tübingen, Germania, 72076
        • Universitatsklinik fur Kinder-und Jugendmedizin Tubingen
      • Florence, Italia
        • AOU Meyer
      • Padova, Italia, 35128
        • Azienda Ospedale University
      • Rome, Italia, 00165
        • Ospedale Pediatrico Bambino Gesu
      • Kuala Lumpur, Malaysia, 59100
        • University of Malaya Medical Center
      • Groningen, Olanda, 9713 GZ
        • Universitair Medisch Centrum Groningen
      • Utrecht, Olanda
        • Wilhelmina Children's Hospital UMCU Utrecht
      • Warsaw, Polonia, 04-730
        • Instytut Pomnik-Centrum Zdrowia Dzieck
      • Birmingham, Regno Unito
        • Birmingham Women's and Children's NHS Foundation Trust
      • London, Regno Unito, SE5 9RS
        • King's College Hospital NHS Foundation Trust King's College Hospital Paediatric Research
    • California
      • San Diego, California, Stati Uniti, 92123
        • Rady Children's Hospital
      • San Francisco, California, Stati Uniti, 94158
        • UCSF
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30329
        • Children's Healthcare of Atlanta
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Riley Hospital for Children at IU Health
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02115
        • Boston Children's Hospital
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64018
        • Children's Mercy Hospital and Clinics
    • New York
      • New Hyde Park, New York, Stati Uniti, 11042
        • Northwell Health System
      • New York, New York, Stati Uniti, 10016
        • Hassenfeld Children's Hospital at NYU Langone
      • New York, New York, Stati Uniti, 10032
        • New York-Presbyterian / Columbia University Irving Medical Center
      • The Bronx, New York, Stati Uniti, 10467
        • The Childrens Hospital at Montefiore Albert Einstein School of Medicine
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27710
        • Atrium Health Carolinas Medical
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45229
        • Cincinnati Children's Hospital
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Oregon Health Science University School of Medicine
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Monroe Carell Jr. Childrens Hospital at Vanderbilt
    • Texas
      • Dallas, Texas, Stati Uniti, 75207
        • Childrens Medical Center of Dallas University of Texas Southwestern
      • Houston, Texas, Stati Uniti, 77030
        • Texas Children's Hospital
      • San Antonio, Texas, Stati Uniti, 78215
        • Texas Liver Institute
      • Istanbul, Turchia (Türkiye)
        • Istanbul University Istanbul Medical Faculty Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Cohort 1 :

  1. Completion of the 24-week Treatment Period of Study A4250-012
  2. Signed informed consent and assent as appropriate. Patients who turn 18 years of age (or legal age per country) during the study will be required to re-consent to remain on the study
  3. Caregivers (and age-appropriate patients) must be willing and able to use an electronic diary (eDiary) device as required by the study
  4. Sexually active males and females must agree to use a reliable contraceptive method with ≤1% failure rate (such as hormonal contraception, intra-uterine device, or complete abstinence) from signed informed consent through 90 days after last dose of study drug.

Cohort 2 :

  1. Infant with clinically confirmed ALGS , ≤11 months of age at Study Day 1
  2. Body weight ≥2 kg at Study Day 1
  3. Gestational age ≥36 weeks. For children born with gestational age between 32 and 36 weeks, a postmenstrual age of ≥36 weeks is required .
  4. Signed parent/legal guardian informed consent.

Exclusion Criteria:

Cohort 1 :

  1. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy
  2. Patients who were not compliant with study drug treatment or procedures in Study A4250-012
  3. Any other conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
  4. Known hypersensitivity to any components of odevixibat

Cohort 2 :

  1. Patient with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:

    1. Biliary atresia of any kind
    2. Progressive familial intrahepatic cholestasis (PFIC)
    3. Benign recurrent intrahepatic cholestasis
  2. Patient with a past medical history or ongoing presence of any other disease or condition known to interfere with the absorption, distribution, metabolism (specifically bile acid metabolism), or excretion of drugs in the intestine, including but not limited to, inflammatory bowel disease

  3. Patient with past medical history or ongoing chronic diarrhea requiring intravenous fluid or nutritional intervention for treatment of the diarrhea and/or its sequelae

  4. Patient has a confirmed past diagnosis of infection with human immunodeficiency virus or other present and active, clinically significant chronic infection

  5. Recent infection requiring hospitalization or treatment with parenteral anti-infective within 4 weeks of Study Day 1 or completion of oral anti-infective treatment within 2 weeks prior to the Screening Visit

  6. Cancer diagnosis (except for basal cell carcinoma)

  7. Chronic kidney disease with an impaired renal function and a glomerular filtration rate <70 mL/min/1.73 m2

  8. Patient with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to the Screening Visit

  9. Patient has had a liver transplant, or a liver transplant is planned within 6 months of Study Day 1

  10. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy

  11. International normalized ratio (INR) >1.4 (the patient may be treated with Vitamin K, and if INR is ≤1.4 at resampling the patient may be enrolled)

  12. Serum alanine aminotransferase (ALT) >10 × upper limit of normal (ULN) at Screening

  13. Serum ALT >15 × ULN at any time point during the last 6 months unless an alternate etiology was confirmed for the elevation

  14. Total bilirubin >15 × ULN at Screening

  15. Patient suffers from uncontrolled, recalcitrant pruritic condition other than ALGS. Examples include, but not limited to, refractory atopic dermatitis or other primary pruritic skin diseases.

  16. Patient exposed to alcohol or substance abuse in utero

  17. Bile acid or lipid binding resins and medications that slow gastrointestinal motility

  18. Patient has had investigational exposure to a drug, biologic agent, or medical device within 30 days prior to the Screening Visit, or 5 half-lives of the study agent, whichever is longer

  19. Any other conditions or abnormalities which, in the opinion of the investigator may compromise the safety of the patient, or interfere with the patient participating in or completing the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Odevixibat (A4250)

Capsules for oral administration once daily for 72 weeks.

Odevixibat is a small molecule and selective inhibitor of IBAT.

Altri nomi:
  • A4250

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Variazione rispetto al basale dei farmaci concomitanti.
Lasso di tempo: Riferimento alla settimana 12 (coorte 2).
Riferimento alla settimana 12 (coorte 2).
Variazione rispetto al basale dei livelli di vitamine liposolubili.
Lasso di tempo: Riferimento alla settimana 12 (coorte 2).
Riferimento alla settimana 12 (coorte 2).
Change from baseline in pruritus
Lasso di tempo: Baseline to week 72 (cohort 1).

Assessed as change in scratching score as measured by measured by the Albireo Observer-Reported Outcome Caregiver Instrument.

Baseline to week 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Lasso di tempo: Baseline to week 12 (cohort 2).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that results in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Physical Examination
Lasso di tempo: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes in Laboratory Parameters
Lasso di tempo: Baseline to week 12 (cohort 2).

The following laboratory parameters will be reported: blood chemistry, hematology and coagulation. The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Vital Signs.
Lasso di tempo: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Variazione rispetto al basale dei livelli sierici degli acidi biliari
Lasso di tempo: Riferimento alla settimana 72 (coorte 1).
Riferimento alla settimana 72 (coorte 1).
Variazione rispetto al basale dei livelli sierici di acidi biliari.
Lasso di tempo: Basale fino alla settimana 72 (coorte 1).
Basale fino alla settimana 72 (coorte 1).
Numero di partecipanti con cambiamento rispetto al basale nell'esame fisico
Lasso di tempo: Riferimento alla settimana 72 (coorte 1).
Riferimento alla settimana 72 (coorte 1).
Numero di partecipanti con variazione rispetto al basale dei segni vitali
Lasso di tempo: Riferimento alla settimana 72 (coorte 1).
Riferimento alla settimana 72 (coorte 1).
Variazione rispetto al basale dei farmaci concomitanti
Lasso di tempo: Riferimento alla settimana 72 (coorte 1).
Riferimento alla settimana 72 (coorte 1).
Variazione rispetto al basale dei risultati dei test di laboratorio Cmax farmacocinetica (PK) [intervallo di tempo: giorno 1, settimana 4, settimana 8 e settimana 12]
Lasso di tempo: Riferimento alla settimana 72 (coorte 1).
Riferimento alla settimana 72 (coorte 1).
Variazione rispetto al basale della concentrazione plasmatica del farmaco in studio
Lasso di tempo: Giorno 1, Settimana 4, Settimana 8 e Settimana 12 (coorte 1).
Giorno 1, Settimana 4, Settimana 8 e Settimana 12 (coorte 1).
Parametri farmacodinamici: variazione dei livelli sierici degli acidi biliari
Lasso di tempo: Riferimento alla settimana 12 (coorte 2).
Riferimento alla settimana 12 (coorte 2).
Change from baseline in patient reported and observer reported itching and scratching severity scores
Lasso di tempo: Baseline to week 72 (cohort 1).

Assessed by the the Albireo ObsRO/ Patient Reported Outcomes (PRO) instruments. The Albireo ObsRO/PRO scratching and itch severity items use 0 to 4 response scales, where each response is distinguished by a unique facial expression, verbal anchor, number, and color code.

Baseline to week 72 (cohort 1).
Percentage of participants achieving a clinically meaningful decrease in pruritus (pruritus responders)
Lasso di tempo: Baseline to week 72 (cohort 1).

Assessed by the Albireo ObsRO/patient reported outcomes (PRO) instruments

Baseline to week 72 (cohort 1).
Change from baseline in sleep parameters.
Lasso di tempo: Baseline to week 72 (cohort 1).

Assessed with the Albireo ObsRO/PRO instruments (e.g: tiredness and number of awakenings).

Baseline to week 72 (cohort 1).
Change from baseline in Pediatric Quality of Life Inventory (PedsQL) scores.
Lasso di tempo: Baseline to week 72 (cohort 1).

The PedsQL instrument consists of 36 questions and uses a 5-point response scales, where higher scores indicates worst symptoms.

Baseline to week 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Patient Global Impression of Improvement (PGIC) score.
Lasso di tempo: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Clinical Global Impression of Improvement (CGIC) score.
Lasso di tempo: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Clinical Global Impression of Change (CGIC) is a clinician-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Caregiver Global Impression of Change (CaGIC) score
Lasso di tempo: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The caregiver Global Impression of Change is a caregiver-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Lasso di tempo: Baseline to week 72 (cohort 1).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that resultes in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 72 (cohort 1).

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Ipsen Medical Director, Ipsen

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

3 settembre 2021

Completamento primario (Stimato)

15 febbraio 2027

Completamento dello studio (Stimato)

15 febbraio 2027

Date di iscrizione allo studio

Primo inviato

13 agosto 2021

Primo inviato che soddisfa i criteri di controllo qualità

1 settembre 2021

Primo Inserito (Effettivo)

5 settembre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

23 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • A4250-015
  • 2023-509028-17-00 (Ctis)
  • 2021-000996-36 (Numero EudraCT)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Periodo di condivisione IPD

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Criteri di accesso alla condivisione IPD

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .